Invivo Therapeutics Holdings Corp (NVIV) reported quarterly earnings results on Thursday, Aug-4-2016. The company said it had a profit of $-0.18 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.02. Analysts had a consensus of $-0.20.
Many Wall Street Analysts have commented on Invivo Therapeutics Holdings Corp. Invivo Therapeutics Holdings Corp was Initiated by Ladenburg Thalmann to “Buy” on Jul 21, 2016. Raymond James Initiated Invivo Therapeutics Holdings Corp on Jul 7, 2016 to “Strong Buy”, Price Target of the shares are set at $13.
Invivo Therapeutics Holdings Corp closed down -0.1 points or -1.57% at $6.25 with 1,17,134 shares getting traded on Tusday. Post opening the session at $6.34, the shares hit an intraday low of $6.24 and an intraday high of $6.52 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on Aug 14, 2015, C Ann Merrifield (director) purchased 2,000 shares at $12.36 per share price.
InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The Company’s technologies incorporate intellectual property licensed under an exclusive around the world license from Boston Children’s Hospital (BCH) and the Massachusetts Institute of Technology (MIT) and intellectual property that has been developed internally including in collaboration with its advisors and partners. The Company intends to leverage its platform technology to develop the Neuro-Spinal Scaffold an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury (SCI). The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.